Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.61 |
| ▸ | LAP3 | P28838 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285380 | 1.00 | LTA4H (0.61) | LTA4HLAP3FFAR1FFAR4MAOB | |
| SCHEMBL3925001 | 1.00 | LTA4H (0.61) | LTA4HLAP3FFAR1FFAR4MAOB | |
| SCHEMBL23340080 | 0.84 | LTA4H (0.61) | LTA4HLAP3FFAR1FFAR4MAOB | |
| SCHEMBL19982072 | 0.84 | LTA4H (0.61) | LTA4HLAP3FFAR1FFAR4MAOB | |
| SCHEMBL79729 | 0.83 | EPHX1 (0.56) | LAP3MAOACYP1A2PTGS1SLC6A2 | |
| SCHEMBL79728 | 0.83 | EPHX1 (0.56) | LAP3MAOACYP1A2PTGS1SLC6A2 | |
| SCHEMBL1263137 | 0.83 | EPHX1 (0.56) | LAP3MAOACYP1A2PTGS1SLC6A2 | |
| SCHEMBL4590113 | 0.81 | EPHX1 (0.54) | LAP3MAOACYP1A2PTGS1SLC6A2 | |
| SCHEMBL2814002 | 0.81 | EPHX1 (0.54) | LAP3MAOACYP1A2PTGS1SLC6A2 | |
| SCHEMBL11230350 | 0.80 | LTA4H (0.50) | LTA4HLAP3FFAR1FFAR4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019157714-A1 | AMPHIPHILIC BLOCK COPOLYMER, NANOPARTICLE CONTAINING THE SAME, MEDICINAL COMPOSITION THEREOF AND METHOD OF INHIBITING RIBONUCLEIC ACID BINDING TO HUMAN ANTIGEN R USING THE SAME | JAN JENG SHIUNG (CN) | 2019-08-22 | — | — | WO | claimed |
| EP-0127899-B1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | The Administrators of The Tulane University Educational Fund (US) | 1987-10-21 | — | — | EP | claimed |
| EP-0188214-A2 | Novel growth hormone-releasing peptides and method of treating mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1986-07-23 | — | — | EP | claimed |
| EP-0145768-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY, David Howard (US) | 1985-06-26 | — | — | EP | claimed |
| WO-1984004916-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY DAVID HOWARD (US) | 1984-12-20 | — | — | WO | claimed |
| EP-0127899-A1 | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1984-12-12 | — | — | EP | claimed |
| WO-2019157714-A1 | AMPHIPHILIC BLOCK COPOLYMER, NANOPARTICLE CONTAINING THE SAME, MEDICINAL COMPOSITION THEREOF AND METHOD OF INHIBITING RIBONUCLEIC ACID BINDING TO HUMAN ANTIGEN R USING THE SAME | JAN JENG SHIUNG (CN) | 2019-08-22 | — | — | WO | disclosed |
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
| EP-0683792-B1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LAB (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0673254-A4 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | disclosed |
| EP-0683792-A4 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | disclosed |
| WO-1984004916-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY DAVID HOWARD (US) | 1984-12-20 | — | — | WO | disclosed |
| EP-0127899-A1 | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1984-12-12 | — | — | EP | disclosed |
| US-4082736-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4082735-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4022760-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022759-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4022761-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | LTA4H 1938/4885LAP3 2058/4885FFAR1 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.